OTC Markets Group uses cookies and similar technologies to help us understand how you use our websites, as further disclosed in our Privacy Policy. Our Terms of Service contain important information including restrictions on your use of our websites. By clicking “Accept”, or by continuing to use our websites, you consent to the use of cookies and agree to the terms of the OTC Markets Group Privacy Policy and Terms of Service.
SRNE
Sorrento Therapeutics, Inc.
Sorrento Therapeutics, Inc.
4955 Directors Place
San Diego, CA 92121
Vuong Trieu, Ph.D., has been involved in drug discovery, development and commercialization for over 25 years, including his contributions as co-inventor of Abraxane. He has served as Chairman and Chief Executive Officer of Oncotelic, Inc. since its formation in 2015. He previously served as Executive Chairman and Interim CEO of Marina Biotech, Inc. from 2016 to 2018. He also served as President and CEO of IgDraSol, Inc. beginning in 2012 until its acquisition by Sorrento Therapeutics, Inc. in 2013. He served as Chief Scientific Officer for Sorrento Therapeutics, Inc. and a member of that company's board of directors from 2013 until 2014. Previously, Dr. Trieu was Sr. Director of Pharmacology/Biology at Abraxis Bioscience/Celgene. Previously, Dr. Trieu held positions at Genetic Therapy/Sandoz, Applied Molecular Evolution/Lily and Parker Hughes Institute. Dr. Trieu holds a PhD in Microbiology, BS in Microbiology and Botany. Dr. Trieu has over 100 patent applications and 39 issued US patents.
Not available
11440 Tomahawk Creek Parkway
Leawood, KS 66211
Not available
Not available
